Status:
COMPLETED
Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects
Lead Sponsor:
InventisBio Co., Ltd
Conditions:
Healthy Female Volunteer
Eligibility:
FEMALE
18-55 years
Phase:
PHASE1
Brief Summary
Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects
Detailed Description
Phase 1, Open Label, Randomized, Single dose, 3 Period, 3 treatment study to evaluation the relative Bioavailability of D-0502 tablet formulation in healthy female subjects
Eligibility Criteria
Inclusion
- Healthy female subjects between the ages of 18-55
- Required evaluation by Investigator for screening and enrollment
- Agreement and compliance with the study and follow-up procedures
Exclusion
- Significant medical history or current comorbidly determined by the Investigator.
- Pregnant or nursing women
Key Trial Info
Start Date :
October 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 11 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT05226338
Start Date
October 27 2021
End Date
May 11 2022
Last Update
August 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labcorp Clinical Research Unit
Daytona Beach, Florida, United States, 32114